免疫治疗超进展的研究进展

Research progress of hyperprogressive disease after immunotherapy

超进展是肿瘤患者在以程序性死亡蛋白-1及其配体(PD-1/PD-L1)抑制剂为代表的免疫治疗中出现的一种新的进展模式,其表现为在抗PD-1/PD-L1免疫治疗后,患者情况恶化,肿瘤加快生长。目前因为其机制尚不明朗及缺少有效的治疗方法,超进展的发生率较高,患者预后较差。

Hyperprogressive disease is a new pattern of progression recently described in patients with cancer treated with immunotherapeutics,which are represented by programmed cell death-1 and programmed cell death ligand-1(PD-1/PD-L1)inhibitors.Hyperprogressive manifests as after anti-PD-1/PD-L1 immunotherapy,the patient′s condition worsens and tumor grows faster.At present,on account of its unclear mechanism and a lack of effective treatment methods,the incidence of hyperprogressive is high and the prognosis of hyperprogressive patients is poor.